And just like that, stocks have landed back in the green. Following a several week long market performance that can only be described as tumultuous, the market notched its best single-day advance in almost twelve years. Driven by Congress’s $2 trillion coronavirus spending bill designed to provide relief from the pandemic’s economic impact, the Dow Jones posted its largest one-day climb since 1933, a more than 11% jump to be precise. As for the S&P 500, it recovered from its lowest point since 2016, with it making its biggest one-day move since October 2008.With it remaining unclear if the improved sentiment has pushed the market to an inflection point, investors are relying on the pros for guidance. One such expert is investing guru James Flynn. The combination of a bachelor’s of science degree in cellular and molecular biology and economics from the University of Michigan and years of experience as an...
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Dan Roberts discuss what Target CEO Brian Cornell says the company is doing amid the coronavirus outbreak, and how Kroger is weathering the outbreak....
Shawn Cruz, TD Ameritrade Trader Strategy Manager, joins Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Jared Blikre to discuss how the markets are being impacted by the coronavirus outbreak....
The Euro has rallied during trading on Wednesday, reaching towards the 1.0850 level before pulling back slightly in early New York trading. That being said though, the market still seems to be struggling in the same area....
The Australian dollar has rallied initially during the trading session on Wednesday, breaking above the 0.60 level. However, it looks as if there are sellers in that particular vicinity, so it’s possible that we have a bit of a short-term ceiling be informed....
The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday. Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers' Celgene unit in 2017 to market and distribute Abraxane. "This decision only applies to the China market and does not impact our ability to supply Abraxane outside of China," Bristol-Myers said in an emailed statement....
The suspension by China National Medical Products Administration is based on inspection findings at Bristol-Myers' contract manufacturing facility in the United States, partner Beigene Ltd said. Beigene and Bristol-Myers were working to restore supply as soon as possible, said the China-based drugmaker, which signed an agreement with Bristol-Myers' Celgene unit in 2017 to market and distribute Abraxane....